[go: up one dir, main page]

WO2024108179A3 - 2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement - Google Patents

2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement Download PDF

Info

Publication number
WO2024108179A3
WO2024108179A3 PCT/US2023/080391 US2023080391W WO2024108179A3 WO 2024108179 A3 WO2024108179 A3 WO 2024108179A3 US 2023080391 W US2023080391 W US 2023080391W WO 2024108179 A3 WO2024108179 A3 WO 2024108179A3
Authority
WO
WIPO (PCT)
Prior art keywords
enhancement
substituted benzofuran
mental disorders
compositions
benzothiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/080391
Other languages
French (fr)
Other versions
WO2024108179A2 (en
Inventor
Matthew J. BAGGOTT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactogen Inc
Original Assignee
Tactogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactogen Inc filed Critical Tactogen Inc
Publication of WO2024108179A2 publication Critical patent/WO2024108179A2/en
Publication of WO2024108179A3 publication Critical patent/WO2024108179A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutically active 2-ethylamine substituted benzofuran and benzothiophene compositions are provided for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes 2-ethylamine substituted benzofuran and benzothiophene compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.
PCT/US2023/080391 2022-11-18 2023-11-17 2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement Ceased WO2024108179A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263426634P 2022-11-18 2022-11-18
US63/426,634 2022-11-18

Publications (2)

Publication Number Publication Date
WO2024108179A2 WO2024108179A2 (en) 2024-05-23
WO2024108179A3 true WO2024108179A3 (en) 2024-06-27

Family

ID=91085557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/080391 Ceased WO2024108179A2 (en) 2022-11-18 2023-11-17 2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement

Country Status (1)

Country Link
WO (1) WO2024108179A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044737A1 (en) * 1999-01-27 2000-08-03 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
US6214859B1 (en) * 1997-08-07 2001-04-10 Fujimoto Brothers Co., Ltd. Ethylamine derivatives
US20080200541A1 (en) * 2005-04-22 2008-08-21 Wyeth Benzofuranyl Alkanamine Derivatives and Uses Thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214859B1 (en) * 1997-08-07 2001-04-10 Fujimoto Brothers Co., Ltd. Ethylamine derivatives
WO2000044737A1 (en) * 1999-01-27 2000-08-03 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
US20080200541A1 (en) * 2005-04-22 2008-08-21 Wyeth Benzofuranyl Alkanamine Derivatives and Uses Thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM COMPOUND 21 March 2013 (2013-03-21), ANONYMOUS: "(2S)-2-(1-benzothiophen-2-yl)- N,2,3-trimethylbutan-1-amine", XP093189591, retrieved from PUBCHEM Database accession no. 71027086 *
SHEVYRIN VADIM, SHAFRAN YURI: "Distinguishing of 2‐MAPB and 6‐MAPB: Solution of the problem", JOURNAL OF MASS SPECTROMETRY, vol. 52, no. 10, 1 October 2017 (2017-10-01), GB , pages 633 - 637, XP093189589, ISSN: 1076-5174, DOI: 10.1002/jms.3970 *

Also Published As

Publication number Publication date
WO2024108179A2 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
WO2020163823A8 (en) Therapeutic agents and methods of treatment
MX2023012981A (en) Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use.
EP1295604A4 (en) PREVENTIVES AND REMEDIES AGAINST DISEASES ASSOCIATED WITH DEMYELINISATION
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
MX2021011488A (en) Compounds and uses thereof.
EA200001258A1 (en) PYRRO-SUBSTITUTED 2-INDOLINONS (OPTIONS), PHARMACEUTICAL COMPOSITION (VARIANTS), METHOD FOR MODULATING PROTEINKINASE CATALYTIC ACTIVITY, METHOD FOR TREATING OR PROPHYLAXIS OF DISTURBANCE IN ORGANISMES OF PHYSICIANS, PREVENTION OR PREVENTION OF DISTURBANCE
ATE492279T1 (en) BUPROPINE METABOLITES FOR THE TREATMENT OF DEMENTIA AND OTHER CEREBROVACCULAR DISEASES
MX2023013338A (en) Derivatives of cannabidiol-c4 for the treatment of epilepsy.
MX2022009384A (en) Therapeutic uses of tirzepatide.
MY124786A (en) Bis-arylsulfones
WO2020154571A8 (en) Compounds and uses thereof
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
CN116829173A8 (en) Pharmaceutical formulations
WO2023107653A3 (en) Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
Latha et al. Efficacy of yoga therapy in the management of headaches.
WO2024108179A3 (en) 2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement
WO2023183613A3 (en) Indolizine compounds for the treatment of mental disorders or inflammation
MX2021015292A (en) Therapeutic interactions of leucomethylthioninium.
GB9723780D0 (en) Regulation of ocular angiogenesis
MX2024011950A (en) T-type calcium channel modulators comprising a piperazine or 1,4-diazepane core and methods of use thereof
WO2023240253A3 (en) Modulators of tnf-alpha activity
WO2024081960A3 (en) Methods to preserve and protect cardiomyocytes and reduce cardiac fibrosis following cardiac injury
WO2024039883A3 (en) Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23892701

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23892701

Country of ref document: EP

Kind code of ref document: A2